Clinical Topics

Some RCC Risk Factors Can Be Modified

by U.S. Medicine

January 1, 2019

SAN ANTONIO—Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study.

A study team from the University of Texas Health Science Center and the South Texas Veterans Healthcare System sought to determine what those are to target disease prevention and reduce healthcare costs.

For an analysis in the journal Urologic Oncology, the researchers used data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, looking at the primary outcome of kidney cancer and focusing on demographics and modifiable risk factors.1

PLCO is a large population-based randomized trial designed and sponsored by the National Cancer Institute to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74. The screening component of the trial was completed in 2006, with participants followed and additional data collected through 2015. 

After missing data were excluded, the researchers analyzed 149,683 participants, noting that 0.5% developed renal cancer. Significantly associated with renal cancer in bivariate analysis (P<0.05) was age, male gender, body mass index, diabetes and hypertension, according to the study team, which added that men have a significant increased risk of kidney cancer over women (hazard ratio [HR] = 1.85; 95% CI: 1.58-2.16; P<0.0001).

Age was identified as a nonmodifiable risk factors associated with kidney

(HR = 1.05; 95% CI: 1.01; 1.05, P = 0.001). Modifiable risk factors include:

  • Obesity measured by body mass index (HR = 1.05; 95% CI: 1.02-1.07; P<0.0001),
  • Hypertension (HR = 1.32; 95% CI: 1.13-1.54; P = 0.0004), and
  • Smoking in pack-years (HR = 1.04; 95% CI: 1.02-1.07; P = 0.0002).

1. Gelfond J, Al-Bayati O, Kabra A, Iffrig K, Kaushik D, Liss MA. Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial. Urol Oncol. 2018 Jul;36(7):340.e1-340.e6. doi: 10.1016/j.urolonc.2018.04.011. Epub 2018 May 17. PubMed PMID: 29779672.


Comments are closed here.


Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up